Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema
about
Anti-vascular endothelial growth factor for proliferative diabetic retinopathyLaser photocoagulation for proliferative diabetic retinopathyAnti-vascular endothelial growth factor for diabetic macular oedemaLaser photocoagulation for diabetic retinopathyLaser photocoagulation for diabetic macular oedemaThe role of aflibercept in the management of diabetic macular edemaReceptor tyrosine kinase-mediated angiogenesisCancer biology in diabetes.The treatment methods for post-stroke visual impairment: A systematic reviewCurrent and future management of diabetic retinopathy: a personalized evidence-based approach.Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysisSwitching to less expensive blindness drug could save medicare part B $18 billion over a ten-year periodAdvances in diabetic retinopathy.Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.Glucocorticoid induction of occludin expression and endothelial barrier requires transcription factor p54 NONOFluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema.Diabetic retinopathy in sub-Saharan Africa: meeting the challenges of an emerging epidemic.Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation.Current status in diabetic macular edema treatments.Subtenon injection of natural leukocyte interferon α-2a in diabetic macular edema: a case report.Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema: a meta-analysis of randomized controlled trialsWnting out ocular neovascularization: using nanoparticle delivery of very-low density lipoprotein receptor extracellular domain as Wnt pathway inhibitor in the retina.Posterior sub-tenon's bevacizumab injection in diabetic macular edema; a pilot study.The effects of anti-vascular endothelial growth factor agents on human retinal pigment epithelial cells under high glucose conditions.Identifying Common Genetic Risk Factors of Diabetic Neuropathies.Anti-VEGF drugs: evidence for effectiveness.Intravitreal Bevacizumab in Vitreous Hemorrhage and Diabetes Mellitus.Translating research into practice.Blood flow suppresses vascular Notch signalling via dll4 and is required for angiogenesis in response to hypoxic signalling.Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice.A proposal for early and personalized treatment of diabetic retinopathy based on clinical pathophysiology and molecular phenotyping.Liquid Biopsy of Vitreous Reveals an Abundant Vesicle Population Consistent With the Size and Morphology of Exosomes.
P2860
Q24187858-C1AB1DFE-B459-4926-814B-10B423954DEBQ24187871-FAF8E09C-E1A3-4FDC-8A85-0E72D775392DQ24193083-3C888069-3359-4B12-A250-AD0900A10357Q24194637-A1B1E7B6-5D23-48F3-BC1B-AF02DBCF5147Q24202632-692AC35B-EBB3-4AB6-8B17-92FEDEDE07D8Q26798348-67C3E4F1-8503-4684-BF63-94BA864132F6Q27001612-FFA7269C-3556-484F-A5B1-D735B7607C20Q33608038-231842DA-3A00-4588-825A-2F93AB19FEA1Q33695324-320E4806-4396-41C8-8F0E-5BDE1C7CFBB8Q33738829-8F5B751F-08FB-4BEC-9617-ADADDF7943B9Q33910289-F74B2D6D-8790-4E4E-82B0-77CC3BE20C19Q34062494-F9BFE498-B367-4D64-AF79-793D0E79D401Q34319662-14B42EE4-8D3A-47C5-A141-F3710ACA44FBQ34558187-1AB567BF-5457-48C3-9D0C-F44A57D029DAQ34703697-6C56E408-412F-43D0-909A-D86D3A13237AQ34758061-E471C698-5884-46CC-B328-562DC9D28C71Q34790721-8EDCC0BF-3DE8-418C-AFEC-BADC70FB0E56Q34987495-EC9BEAB3-B2C5-41FF-9203-946ADC172227Q35023708-0411FB88-E92E-4D7B-87D5-1FE3C6A8BA2DQ35027317-EAF76C9C-042B-409A-B462-720B6D398153Q35534298-687C751D-2937-4EDD-9920-BB20E46C37FDQ35597138-97146B08-6BCF-4E5A-9739-8B7B4C531987Q36221554-31D9B6D3-5964-4D02-8744-CB46FB90BDB8Q37647798-2DCD42BD-53E7-4EDE-8A6B-D28BD6472972Q38527798-5A800072-17BD-4174-A197-46609BDE04A7Q38996348-1218EEFB-AA90-4426-9714-75E34ADE0D4BQ42292548-24BDCE11-5BC9-415B-8961-68752BA7CEF3Q42409934-2607CF25-11E1-4E7A-B0C1-6CD7BAB987B3Q42678883-D307AA56-989A-41C5-86EA-3BE2B3CC7435Q49275652-D9D17212-2365-4250-979F-6836BECFF2B9Q53336179-4C6FB80E-CDCD-441F-B589-31545DCA525CQ53818398-C42EB6E7-A1E7-4C72-BAD6-89DF067E193A
P2860
Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Antiangiogenic therapy with an ...... es for diabetic macular oedema
@ast
Antiangiogenic therapy with an ...... es for diabetic macular oedema
@en
Antiangiogenic therapy with an ...... es for diabetic macular oedema
@en-gb
Antiangiogenic therapy with an ...... es for diabetic macular oedema
@nl
type
label
Antiangiogenic therapy with an ...... es for diabetic macular oedema
@ast
Antiangiogenic therapy with an ...... es for diabetic macular oedema
@en
Antiangiogenic therapy with an ...... es for diabetic macular oedema
@en-gb
Antiangiogenic therapy with an ...... es for diabetic macular oedema
@nl
prefLabel
Antiangiogenic therapy with an ...... es for diabetic macular oedema
@ast
Antiangiogenic therapy with an ...... es for diabetic macular oedema
@en
Antiangiogenic therapy with an ...... es for diabetic macular oedema
@en-gb
Antiangiogenic therapy with an ...... es for diabetic macular oedema
@nl
P2093
P2860
P1476
Antiangiogenic therapy with an ...... es for diabetic macular oedema
@en
P2093
Francesca Menchini
Mariacristina Parravano
Massimo Brunetti
P2860
P356
10.1002/14651858.CD007419.PUB3
P577
2012-12-12T00:00:00Z